FilingSEC EDGAR8-K
Scribe Therapeutics Reports Clinical Trial Initiation and IPO Completion
· SEC accepted
StagePhase 1
Filing content
Scribe Therapeutics announced the initiation of a Phase 1 trial for STX-1150 and the completion of an IPO and private placement, raising approximately $155.5 million in aggregate gross proceeds.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…